INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806.

Parminder Singh,Cathy Tangen,Jason A. Efstathiou,Seth P. Lerner,Sameer G. Jhavar,Noah M. Hahn,Brian Addis Costello,Srikala S. Sridhar, Weliang Du,Joshua J. Meeks,Bishoy Morris Faltas,Petros Grivas,Felix Y Feng,Ronald C. Chen,Alicia K. Morgans,Amit Gupta, Richard Carlton Bangs,Kathryn A. Winter,Nicholas J. Vogelzang,Ian Murchie Thompson

Journal of Clinical Oncology（2020）

引用 6|浏览6

暂无评分

摘要

TPS586Background: Chemoradiotherapy(CRT) is a SOC for patients with muscle invasive bladder cancer (MIBC) who refuse or are not fit for radical cystectomy. Radiotherapy and chemotherapy are known t...

查看译文

关键词

Chemoradiotherapy,Bladder cancer,Atezolizumab,Cystectomy,Radiation therapy,Chemotherapy,Randomized controlled trial,Urology,Medicine,Muscle invasive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要